Yang Y, Zhang X. An overview of extrahepatic cholangiocarcinoma: from here to where? Front Oncol. 2023;13:1171098.

Article  PubMed  PubMed Central  CAS  Google Scholar 

National Comprehensive Cancer Network. Biliary tract cancers (version 2.2023) [Available from: https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf. Accessed 5/1/23

Folseraas T, Boberg KM. Cancer risk and surveillance in primary sclerosing cholangitis. Clin Liver Dis. 2016;20(1):79–98.

Article  PubMed  Google Scholar 

Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol. 2022;77(6):1690–8.

Article  PubMed  Google Scholar 

Petrick JL, Yang B, Altekruse SF, Van Dyke AL, Koshiol J, Graubard BI, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based study in SEER-Medicare. PLoS One. 2017;12(10): e0186643.

Article  PubMed  PubMed Central  Google Scholar 

Farha N, Dima D, Ullah F, Kamath S. Precision oncology targets in biliary tract cancer. Cancers (Basel). 2023;15(7):2105. https://doi.org/10.3390/cancers15072105.

Jiang Y, Jiang L, Li F, Li Q, Yuan S, Huang S, et al. The epidemiological trends of biliary tract cancers in the United States of America. BMC Gastroenterol. 2022;22(1):546.

Article  PubMed  PubMed Central  Google Scholar 

Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56(2):69–83.

Article  PubMed  Google Scholar 

Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428–44.

Article  PubMed  CAS  Google Scholar 

Ali H, Zweigle J, Patel P, Tedder B, Khan R, Agrawal S. Survival analysis of extrahepatic cholangiocarcinoma based on surveillance, epidemiology, and end results database. Ann Hepatobiliary Pancreat Surg. 2023;27(2):151–7.

Article  PubMed  PubMed Central  Google Scholar 

Society AC. Survival rates for bile duct cancer 2018 [Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8554.00.pdf. Accessed 5/1/23

Ethun CG, Le N, Lopez-Aguiar AG, Pawlik TM, Poultsides G, Tran T, et al. Pathologic and prognostic implications of incidental versus nonincidental gallbladder cancer: a 10-institution study from the United States extrahepatic biliary malignancy consortium. Am Surg. 2017;83(7):679–86.

Article  PubMed  PubMed Central  Google Scholar 

Tabibian JH, Masyuk AI, Masyuk TV, O’Hara SP, LaRusso NF. Physiology of cholangiocytes. Compr Physiol. 2013;3(1):541–65.

Article  PubMed  Google Scholar 

Gkountakos A, Martelli FM, Silvestris N, Bevere M, De Bellis M, Alaimo L, Sapuppo E, Masetto F, Mombello A, Simbolo M, Bariani E, Milella M, Fassan M, Scarpa A, Luchini C. Extrahepatic distal cholangiocarcinoma vs. pancreatic ductal adenocarcinoma: Histology and molecular profiling for differential diagnosis and treatment. Cancers (Basel). 2023;15(5):1454. https://doi.org/10.3390/cancers15051454

Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabro R, Pinyol R, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020;73(2):315–27.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu S, Ren J, Ten Dijke P. Targeting TGFbeta signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):8.

Article  PubMed  PubMed Central  Google Scholar 

Gradilone SA, Radtke BN, Bogert PS, Huang BQ, Gajdos GB, LaRusso NF. HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res. 2013;73(7):2259–70.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–61.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rizzo A, Tavolari S, Ricci AD, Frega G, Palloni A, Relli V, Salati M, Fenocchio E, Massa A, Aglietta M, Brandi G. Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures. Cancers (Basel). 2020;12(11):3256. https://doi.org/10.3390/cancers12113256.

Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838–47.

Article  PubMed  CAS  Google Scholar 

Malats N, Porta M, Piñol JL, Corominas JM, Rifà J, Real FX. Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer. PANK-ras I Project Investigators. J Clin Oncol. 1995;13(7):1679–86.

Article  PubMed  CAS  Google Scholar 

Mondaca S, Nervi B, Pinto M, Abou-Alfa GK. Biliary tract cancer prognostic and predictive genomics. Chin Clin Oncol. 2019;8(4):42.

Article  PubMed  PubMed Central  Google Scholar 

Jacobi O, Ross JS, Goshen-Lago T, Haddad R, Moore A, Sulkes A, et al. ERBB2 pathway in biliary tract carcinoma: clinical implications of a targetable pathway. Oncol Res Treat. 2021;44(1–2):20–7.

Article  PubMed  CAS  Google Scholar 

Moffat GT, Hu ZI, Armas ADD, Ross JS, Javle MM, Knox JJ. Characterizing KRAS allele variants within biliary tract cancers. J Clin Oncol. 2023;41(16_suppl):4088-.

• Spencer K, Pappas L, Baiev I, Maurer J, Bocobo AG, Zhang K, et al. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. J Natl Cancer Inst. 2023. This is an important reference for discussing key molecular features and genomic profiles that distinguish eCCA from iCCA.

Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751–65.

Article  PubMed  PubMed Central  Google Scholar 

Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev. 2021;95: 102170.

Article  PubMed  CAS  Google Scholar 

de Bitter TJJ, de Reuver PR, de Savornin Lohman EAJ, Kroeze LI, Vink-Borger ME, van Vliet S, et al. Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients. NPJ Precis Oncol. 2022;6(1):83.

Article  PubMed  PubMed Central  Google Scholar 

Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, et al. Cholangiocarcinoma - novel biological insights and therapeutic strategies. Nat Rev Clin Oncol. 2023;20(7):470–86.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mondaca S, Schultz N, Roa JC, Walch HS, Sepulveda S, Harding JJ, et al. Clinical and genomic characterization of ERBB2-altered gallbladder cancer. J Clin Oncol. 2022;40(16_suppl):4114-.

Giraldo NA, Drill E, Satravada BA, Dika IE, Brannon AR, Dermawan J, et al. Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention. Clin Cancer Res. 2022;28(24):5359–67.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Snyder RA. Survival benefit of neoadjuvant therapy for extrahepatic cholangiocarcinoma: real or artifact? Ann Surg Oncol. 2023;30(1):15–7.

Article  PubMed  Google Scholar 

De Moura DTH, Moura EGH, Bernardo WM, De Moura ETH, Baraca FI, Kondo A, et al. Endoscopic retrograde cholangiopancreatography versus endoscopic ultrasound for tissue diagnosis of malignant biliary stricture: systematic review and meta-analysis. Endosc Ultrasound. 2018;7(1):10–9.

Article  PubMed  Google Scholar 

Brooks C, Gausman V, Kokoy-Mondragon C, Munot K, Amin SP, Desai A, et al. Role of fluorescent in situ hybridization, cholangioscopic biopsies, and EUS-FNA in the evaluation of biliary strictures. Dig Dis Sci. 2018;63(3):636–44.

Article  PubMed  CAS  Google Scholar 

Juratli MA, Hofmann K, Balaban U, El Youzouri H, Pession U, Heise M, et al. Introduction of an interdisciplinary tumor board leads to improvement of treatment outcome of cholangiocarcinoma (bile duct cancer). Chirurg. 2020;91(8):650–61.

Article  PubMed  Google Scholar 

Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015–27.

Article  PubMed  Google Scholar 

Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review. Cancer Treat Res Commun. 2021;27: 100354.

Article  PubMed  Google Scholar 

Radtke A, Konigsrainer A. Surgical therapy of cholangiocarcinoma. Visc Med. 2016;32(6):422–6.

Article  PubMed  PubMed Central  Google Scholar 

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18(3):651–8.

Article  PubMed  Google Scholar 

Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klumpen HJ, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;15:564.

Article  PubMed  PubMed Central  Google Scholar 

Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658–67.

Article  PubMed  CAS  Google Scholar 

Yamamoto R, Sugiura T, Ashida R, Ohgi K, Yamada M, Otsuka S, et al. Prognostic value of carbohydrate antigen 19–9 and the surgical margin in extrahepatic cholangiocarcinoma. Ann Gastroenterol Surg. 2022;6(2):307–15.

Article  PubMed